Invesco Ltd. filed an amended Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 1,261,037 shares of Collegium Pharmaceutical Inc. common stock as of September 30, 2026.

Key Highlights

  • Beneficial ownership: Invesco Ltd. reported beneficial ownership of 1,261,037 shares of Collegium Pharmaceutical Inc. common stock.
  • Percent of class: The reported stake represents 3.9% of the issuer's outstanding common stock.
  • Sole voting power: Invesco Ltd. holds sole power to vote or direct the vote of 1,260,828 shares.
  • Sole dispositive power: Invesco Ltd. holds sole power to dispose of or direct the disposition of 1,261,037 shares.
  • No shared voting or dispositive power: Shared voting power and shared dispositive power are each reported as 0.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Subsidiaries involved: The filing identifies Invesco Advisers, Inc. and Invesco Capital Management LLC as the relevant subsidiaries through which the shares are held.

Invesco Ltd. Discloses Sub-5% Position in Collegium Pharmaceutical via Amendment

According to the filing, Invesco Ltd., organized in Bermuda and headquartered at 1331 Spring Street NW, Suite 2500, Atlanta, GA 30309, submitted this Schedule 13G as Amendment No. 1, acting in its capacity as a parent holding company to its investment advisers. The shares reported are held of record by clients of Invesco Ltd. The filing identifies Invesco Advisers, Inc. and Invesco Capital Management LLC as the relevant subsidiaries that acquired the securities being reported. The issuer, Collegium Pharmaceutical Inc., is listed on NASDAQ:COLL and is headquartered at 100 Technology Center Drive, Suite 300, Stoughton, MA 02072.

The filing states that Invesco Ltd. "may be deemed to beneficially own 1,261,037 shares of the Issuer which are held of record by clients of Invesco Ltd." The aggregate beneficial ownership of 1,261,037 shares represents 3.9% of the class, placing this disclosure under Item 5, ownership of 5 percent or less of a class. No shared voting or dispositive power was reported. The filing further states that no single person holds greater than 5% economic ownership in the securities listed, and that the relevant clients of Invesco Ltd. retain the right to receive dividends and proceeds from the sale of the securities.

The document was signed by Robert R. Leveille, Global Head of Compliance for Invesco Ltd., on November 9, 2026. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Invesco Ltd. filed an amended Schedule 13G disclosing beneficial ownership of 1,261,037 shares, or 3.9%, of Collegium Pharmaceutical Inc. common stock as of September 30, 2026, held through client accounts managed by its investment adviser subsidiaries.